|
MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma …
MarketWatch (press release) MediciNova intends to design pivotal trial(s) that will include technological and operational improvements and further controls for medications that are not typically used in the treatment of acute exacerbations of asthma and were over-represented in … MediciNova (MNOV) Says Results of Phase 2B Trial of MN-221 Didn't Meet Primary … |
View full post on asthma – Google News